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Background: Pediatric pancreatitis is an underdiagnosed disease with variable etiology. In the past 10e15
years the incidence of pediatric pancreatitis has increased, it is now 3.6e13.3 cases per 100,000 children.
Up-to-date evidence based management guidelines are lacking for the pediatric pancreatitis. The Eu-
ropean Pancreatic Club, in collaboration with the Hungarian Pancreatic Study Group organized a
consensus guideline meeting on the diagnosis and management of pancreatitis in the pediatric
population.
Methods: Pediatric Pancreatitis was divided into three main clinical categories: acute pancreatitis, acute
recurrent pancreatitis and chronic pancreatitis. Fifteen relevant topics (acute pancreatitis: diagnosis;
etiology; prognosis; imaging; complications; therapy; biliary tract management; acute recurrent
pancreatitis: diagnosis; chronic pancreatitis: diagnosis, etiology, treatment, imaging, intervention, pain,
complications; enzyme replacement) were deﬁned. Ten experts from the USA and Europe reviewed and
summarized the available literature. Evidence was classiﬁed according to the GRADE classiﬁcation
system.
Results: Within ﬁfteen topics, forty-seven relevant clinical questions were deﬁned. The draft of the
updated guideline was presented and discussed at the consensus meeting held during the 49th Meeting
of European Pancreatic Club, in Budapest, on July 1, 2017.can Pancreatic Association; CFTR, cystic ﬁbrosis transmembrane regulator; CPA1, Carboxypeptidase A1; CP, chronic
che Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (German Society for Digestive and
EBMG, evidence-based medicine guidelines; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic
d ﬁne-needle aspiration; FCSEMS, fully covered self-expanding metal stent; HPSG, Hungarian Pancreatic Study Group;
inﬂammatory bowel disease; WON, walled-off necrosis; RCT, randomized controlled trial; PERT, pancreatic enzyme
ciency.
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A. Parniczky et al. / Pancreatology 18 (2018) 146e160 147Conclusions: These evidence-based guidelines provides the current state of the art of the diagnosis and
management of pediatric pancreatitis.
© 2018 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Inﬂammation of the pancreas in children is rarely diagnosed and
the etiologies are diverse. Pediatric acute and acute recurrent
pancreatitis are signiﬁcantly more common than it was previously
presumed and depending on the nature of the disease, it can lead to
chronic pancreatitis (CP). The most common causes are trauma,
structural anomalies, infection, systemic disease, medication or
biliary disease and genetic etiologies. In most cases, pediatric
pancreatitis (PP) is mild with good prognosis. In the last 10e15
years, the incidence of pediatric pancreatitis has been on the rise.
The incidence based on international data is 3.6e13.3 cases per
100,000 children, while data regarding CP are lacking [1]. There is
great variability in the severity, clinical progression and late com-
plications of the disease.
Having a signiﬁcant effect on the life of the children and parents
PP requires up-to-date and evidence -based treatment approaches.
Owing to the initiative of the International Association of Pan-
creatology (IAP) and the American Pancreatic Association (APA),
with international and multidisciplinary collaboration, a modern
and evidence-based treatment guideline for acute pancreatitis (AP)
in adults were drafted in 2012, and published in 2013. In 2012, the
German Society of Digestive and Metabolic Diseases (DGVS) also
published a similar guideline for CP [2]. The International Study
Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE) was
founded in 2010 described the ﬁrst ever pediatric deﬁnition of AP,
ARP and CP [3] and developed consensus guidelines for evaluation
of pediatric ARP, CP and its risk factors [4e6]. Hungarian Pancreatic
Study Group (HPSG) developed the ﬁrst evidence-based medicine
(EBM) management guideline in PP in 2014 and published it in
2015 in Hungarian [7]. There were plenty of requests from pedia-
tricians from all over the world to make it available in English,
therefore, the European Pancreatic Club (EPC), in collaborationwith
the Hungarian Pancreatic Study Group (HPSG) organized a
consensus guideline meeting to generate a report on the diagnosis
and management of pediatric pancreatitis.
Objective
The aim of EPC and HPSG is to establish evidence-based
guidelines for the diagnosis and management of PP (PP-EBM) by
thoroughly reviewing, summarizing and discussing the interna-
tional studies and existing adult guidelines, expanding them if
necessary and in case of agreement, implementing them in the
world. Our fundamental goal is to improve patient management,
assist medical providers make clinical decisions and to help the
ﬁnancial regulatory authorities establish the grounds for an EBM
based patient-care system.
Methods
Preparation process of the guideline
1) Two of the investigators translated the 2015 HPSG PP-EBM into
English.
2) Ten investigators (experts from pediatric pancreatitis) extended,
modiﬁed and reviewed the questions and answers and addedtheir own propositions, which were included in the ﬁrst draft of
the revised PP-EBM.
3) The consensus meeting was held on July 1, 2017 in Budapest as
part of the 49th European Pancreatic Club Meeting 2017. The
consensus meeting was open for all delegates who attended the
conference. In order to get the highest quality PP-EBM, four key
multidisciplinary experts (in pediatrics, endoscopy, surgery and
gastroenterology) were invited. Attendees were allowed to
suggest modiﬁcations to the draft recommendations. All at-
tendees voted on the strength of the consensus via a secret
balloting system. The event was recorded for documentation
purposes.
4) The members of the consensus panel received the ﬁnished PP-
EBM for another review.Classiﬁcation of the evidence
The classiﬁcation of the evidence was based on the GRADE
Working Group internationally accepted system, which was
established in 2011 (www.gradeworkinggroup.org). These criteria
are presented in Table 1.
Degree of consensus
Recommendation: the strength of the GRADE recommendation
(1¼ strong, 2¼weak), the quality of the evidence (A¼ high,
B¼moderate, C¼ low), and the strength of the international ex-
perts' consensus (strong/weak) are indicated.
The participating members determined the strength of the
consensus by voting yes or no. Degrees of consensus were as fol-
lows: 95% or more ‘yes’ votes were considered ‘full agreement’; at
least 70% ‘yes’ votes indicated ‘strong agreement’, and more than
50% ‘yes’ votes were regarded as ‘weak agreement’. (See Table 2).
Acute pediatric pancreatitis (PP)
AP-I. Diagnosis and deﬁnition
AP-I.1. A diagnosis of AP is achieved by meeting at least 2 of the
following 3 criteria: 1) abdominal pain; 2) serum lipase or serum
amylase level at least three times greater than the upper limit of
normal; 3) characteristic ﬁndings of AP with imaging methods.
(GRADE 1/B, full agreement)
AP-I.2. Diffuse, epigastric, persistent or minimally easing
abdominal pain suggests AP in childhood. (GRADE 1/C, full
agreement)
AP-I.3. In children, especially in infants and in toddlers, vomit-
ing, irritability, abdominal distension may suggest AP. (GRADE 1/B,
full agreement)
AP-I.4. Measurement of serum amylase and/or lipase among
the routine laboratory tests is recommended in presence of
abdominal pain. (GRADE 1/C, full agreement)
AP-II. Etiology
AP-II. Etiological factors that should be considered after the
Table 1
Grading tutorial (www.uptodate.com/home/grading-tutorial).
Grade of
Recommendation
Clarity of risk/beneﬁt Quality of supporting evidence Implications
1A.
Strong
recommendation.
High quality
evidence.
Beneﬁts clearly outweigh risks and
burdens, or vice versa.
Consistent evidence from well-performed randomized,
controlled trials or overwhelming evidence of some other
form. Further research is unlikely to change our conﬁdence in
the estimate of beneﬁt and risk.
Strong recommendation, can apply to
most patients in most circumstances
without reservation.
1B.
Strong
recommendation.
Moderate quality
evidence.
Beneﬁts clearly outweigh risks and
burdens, or vice versa.
Evidence from randomized, controlled trials with important
limitations (inconsistent results, methodologic ﬂaws, indirect
or imprecise), or very strong evidence of some other form.
Further research (if performed) is likely to have an impact on
our conﬁdence in the estimate of beneﬁt and risk and may
change the estimate.
Strong recommendation, likely to apply
to most patients.
1C.
Strong
recommendation.
Low quality
evidence.
Beneﬁts appear to outweigh risks and
burdens, or vice versa.
Evidence from observational studies, unsystematic clinical
experience, or from randomized, controlled trials with serious
ﬂaws. Any estimate of effect is uncertain.
Relatively strong recommendation;
might change when higher quality
evidence becomes available.
2A.
Weak
recommendation.
High quality
evidence.
Beneﬁts closely balanced with risks and
burdens.
Consistent evidence from well-performed randomized,
controlled trials or overwhelming evidence of some other
form. Further research is unlikely to change our conﬁdence in
the estimate of beneﬁt and risk.
Weak recommendation, best action may
differ depending on circumstances or
patient or societal values.
2B.
Weak
recommendation.
Moderate quality
evidence.
Beneﬁts closely balanced with risks and
burdens, some uncertainty in the
estimates of beneﬁts, risks and burdens.
Evidence from randomized, controlled trials with important
limitations (inconsistent results, methodological ﬂaws,
indirect or imprecise), or very strong evidence of some other
form. Further research (if performed) is likely to have an
impact on our conﬁdence in the estimate of beneﬁt and risk
and may change the estimate.
Weak recommendation, alternative
approaches likely to be better for some
patients under some circumstances.
2C.
Weak
recommendation.
Low quality
evidence.
Uncertainty in the estimates of beneﬁts,
risks, and burdens; beneﬁts may be closely
balanced with risks and burdens.
Evidence from observational studies, unsystematic clinical
experience, or from randomized, controlled trials with serious
ﬂaws. Any estimate of effect is uncertain.
Very weak recommendation; other
alternatives may be equally reasonable.
Table 2
Summary of deﬁnitions.
Deﬁnition of acute pancreatitis (AP)
The ﬁrst acute episode of pediatric pancreatitis occurs before the age of 18 years [1]. The diagnosis of AP is made by meeting at least 2 of the following 3 criteria: 1)
abdominal pain; 2) serum lipase or serum amylase level at least three times greater than the upper limit of normal; 3) characteristic ﬁndings of AP with imaging
methods [3].
Deﬁnition of acute recurrent pancreatitis (ARP)
It is deﬁned by at least 2 acute attacks in a year or more than 3 in the patient's lifetime without any evidence of CP [3,8]. There must be complete resolution of pain (1
month pain-free interval between the diagnoses of AP, or complete normalization of serum pancreatic enzyme levels (amylase and lipase), before the subsequent
episode of AP is diagnosed, along with complete resolution of pain symptoms, irrespective of a speciﬁc time interval between AP episodes [2,8]. Studies suggest that
children who had AP have a 10e35% chance of another attack [9].
Deﬁnition of chronic pancreatitis (CP)
It is an irreversible inﬂammatory process, which leads to changes in the pancreatic parenchyma and function. Documentation of characteristic histological and
morphological alterations or decreased exocrine or endocrine pancreas function is needed to establish the diagnosis [3].
A. Parniczky et al. / Pancreatology 18 (2018) 146e160148diagnosis is reached are the following: biliary and pancreatic ab-
normalities, medication-associated, presence of underlying sys-
temic disease, trauma, genetic predisposition, infection, metabolic
disorders and autoimmune pancreatitis. (GRADE 1/C, full agreement)
AP-II.1. Pancreaticobiliary anomalies should be ruled out in
cases of ARP. (GRADE 2/C, full agreement)
AP-II.2. Cystic ﬁbrosis should be evaluated functionally by per-
forming a sweat chloride measurement (pilocarpine iontopho-
resis). (GRADE 2C, full agreement)
AP-II.3. In patients with a second episode of idiopathic AP or a
ﬁrst episode of idiopathic AP and a family history of AP or CP, full
sequence analysis of the PRSS1, CPA1, SPINK1, CTRC and CFTR gene
exons and exon-intron boundaries and testing for the CEL gene
pathogenic hybrid allele is recommended in order to explore the
etiological background. (GRADE 1/A, full agreement)
AP-III. Prognostic factors: Currently, there is no pediatric-
speciﬁc clinical prognostic system which can be recommended.(GRADE 2/C, full agreement)AP-IV. Imaging
AP-IV.1. Transabdominal ultrasonography is recommended as a
ﬁrst-choice imaging technique in pediatric AP. (GRADE 1/B, full
agreement)
AP-IV.2. Contrast-enhanced abdominal computed tomography
(CT) is recommended in clinical deterioration in children as per
adult guidelines. (Adult evidence level: GRADE 1/C, full agreement)
AP-IV.3. If the clinical presentation of the child suggests
pancreatic necrosis contrast-enhanced abdominal CT or MRI is
recommended, as per adult guidelines. The optimal timing of the
scan is at least 72e96 h after presentation with pancreatitis. (Adult
evidence level: GRADE 1/B, full agreement)
AP-IV.4. ERCP is not recommended for diagnostic purposes.
(GRADE 1/C, strong agreement)
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children in cases of suspected autoimmune or biliary pancreatitis or
for treatment of local complications, such as pseudocysts or walled-
off necrosis (WON). (GRADE 2/C, full agreement)
AP-IV.6.MRCP is recommended for suspected pancreatic ductal
leak or injury or suspected biliary tract abnormalities. (GRADE 2/C,
full agreement)
AP-V. Therapy
AP-V.1. Fluid replacement therapy
AP-V.1.1. Administration of dextrose containing crystalloids is
recommended as the initial choice for replacement ﬂuid therapy in
AP. (GRADE 2/B, full agreement)
AP-V.1.2. Due to lack of unequivocal guidelines, early aggressive
ﬂuid management (at a rate of more than 1.5e2 times the main-
tenance rate of IV ﬂuids) is recommended in children in the ﬁrst
24 h. (GRADE 2/C, full agreement)
AP-V.2. Analgesia: Analgesia should be provided when indi-
cated. No speciﬁc pain management guidelines are available in
pediatric AP. (GRADE 2/C, full agreement)
AP-V.3. Nutrition
AP-V.3.1. Oral feeding can be started as soon as tolerated even in
the presence of systemic inﬂammation and before the amylase or
lipase values have decreased. (Adult evidence level: GRADE 2/B, full
agreement)
AP-V.3.2. If adequate oral feeding is not tolerated or the required
calories cannot be achieved by oral feeding within 72 h, enteral
tube feeding is recommended. (Adult evidence level: GRADE 1/A, full
agreement)
AP-V.3.3. In AP, enteral nutrition can be achieved either via
nasogastric or nasojejunal tube feedings. There are no comparative
studies between gastric and jejunal feeding in pediatric AP. (Adult
evidence level: GRADE 1/A, full agreement)
AP-V.3.4. Elemental and polymeric formulas are both appro-
priate in the management of AP. (Adult evidence level: GRADE 2/B,
full agreement)
AP-V.3.5. Complete parenteral feeding is used as a second-line
treatment in AP when enteral nutrition is not tolerable for the
patient and additional nutrition is necessary. (Adult evidence level:
GRADE 1/A, full agreement)
AP-V.4. Antibiotic therapy
AP-V.4.1. Regardless of the severity of the pancreatitis or exist-
ing necrosis, routine use of prophylactic antibiotics is not recom-
mended in AP. (Adult evidence level: GRADE 1/B, strong agreement)
AP-V.4.2. In cases of systemic infectious complications, chol-
angitis or suspected infected pancreatic necrosis, antibiotic treat-
ment is recommended. (GRADE 1/B, full agreement); AP-VI.
Management of biliary pancreatitis
AP-VI.1. ERCP is not indicated in predicted mild biliary pancre-
atitis without cholangitis. (Adult evidence level: GRADE 1/A, full
agreement)
ERCP is probably not indicated in predicted severe biliary
pancreatitis without cholangitis. (Adult evidence level: GRADE 1/B,
full agreement)
ERCP is probably indicated in biliary pancreatitis with common
biliary obstruction.
(Adult evidence level: GRADE 1/C, full agreement)
ERCP is indicated patients with biliary pancreatitis and chol-
angitis. (Adult evidence level: GRADE 1/B, full agreement)
AP-VI.2. In cases of severe cholangitis ERCP should be done
urgently within 24 h. In other cases of cholangitis and/or obstruc-
tion. ERCP should be performed within 72 h. (Adult evidence level:GRADE 1/B, full agreement)
AP-VI.3. For uncomplicated biliary pancreatitis, cholecystec-
tomy is recommended during the index admission if possible or, if
not possible, within 30 days of the ﬁrst admission for mild
cholelythiasis-associated AP in children. Importantly, if cholecys-
tectomy is not performed, the patient remains at risk of another
episode of AP and complications of gallstones. (Adult evidence level:
GRADE 1/B, full agreement; Pediatric evidence level: GRADE 1/C, full
agreement)
AP-VII. Complications
AP-VII.1. Common indications for intervention in necrotizing
pancreatitis include:
1) Conﬁrmed cases of infected necrotizing pancreatitis or if strong
suspicion of the same with decline in clinical status, especially
with WON.
2) Unconﬁrmed cases of infected necrotizing pancreatitis with
multiple organ failure, especially with WON.
3) Abdominal compartment syndrome
4) Ongoing acute bleeding
5) Bowel ischemia
6) WON causing gastric outlet, bowel or biliary obstruction
(Adult evidence level: GRADE 1/C, full agreement)
AP-VII.2. Routine percutaneous ﬁne-needle aspiration (FNA) of
peripancreatic necrotic collections is unnecessary for conﬁrming
bacterial infection, as clinical (continuous fever, elevated inﬂam-
matorymarkers) and imaging signs (gas in the collections) are valid
predictors of infection necrosis in majority of the cases. FNA could
helpwith the conﬁrmation of infection, but there is high prevalence
of false negatives (12e25%). (Adult evidence level: GRADE 1/C, full
agreement)
AP-VII.3. Regarding the optimal timing of intervention in sus-
pected and conﬁrmed cases of infected pancreatic necrosis, only
adult recommendations are available, relevant clinical pediatric
studies have not been conducted. In conﬁrmed or suspected
infected necrotizing pancreatitis, invasive intervention (percuta-
neous catheter drainage, endoscopic transluminal drainage or
necrosectomy) should be delayed as much as possible, but at least
by 4 weeks after the initial presentation so that the collection can
transform intoWON. The timing of intervention should be balanced
between the need to intervene and the beneﬁts of delaying the
intervention. (Adult evidence level: GRADE 1/C, full agreement)
AP-VII.4. The optimal intervention strategy in cases of suspected
or conﬁrmed infected necrotizing pancreatitis is initially imaging-
guided percutaneous (retroperitoneal) catheter drainage or endo-
scopic transluminal drainage, which, if necessary, can be followed
by endoscopic or surgical necrosectomy. (Adult evidence level:
GRADE 1/B, full agreement)
AP-VII.5. In the cases of an asymptomatic pancreatic pseudo-
cysts, regardless of size, location, and/or extension observation is
appropriate. When pancreatic pseudocysts are symptomatic,
endoscopic intervention should be the therapy of ﬁrst choice in
experienced centers. (Adult evidence level: GRADE 1/C, full
agreement)
Acute recurrent pancreatitis (ARP) in children
ARP. Deﬁnition: It is deﬁned by at least 2 acute attacks in the
patient's lifetime without any evidence of CP. There must be com-
plete resolution of pain (1 month pain-free interval between the
diagnoses of AP, or complete normalization of serum pancreatic
enzyme levels (amylase and lipase), before the subsequent episode
A. Parniczky et al. / Pancreatology 18 (2018) 146e160150of AP is diagnosed, along with complete resolution of pain symp-
toms, irrespective of a speciﬁc time interval between AP episodes.
(GRADE 2/B, full agreement).
Chronic pancreatitis (CP) IN children
CP-I. Diagnosis and deﬁnition: CP is a progressive inﬂamma-
tory process that leads to the destruction of pancreatic parenchyma
and has a negative impact on pancreatic function. The diagnosis of
CP requires characteristic histological and morphological ﬁndings
with decreased pancreatic function (endocrine or exocrine).
(GRADE 1/B, strong agreement).
CP-II. Etiological factors in childhood onset CP
CP-II.1. Genetic variations are the most common risk factors for
development of pediatric CP. (GRADE 1/A, full agreement) However,
other risk factors such as obstruction, autoimmune and toxic and
metabolic factors also need to be examined. (GRADE 2/B, full
agreement)
CP-II.2. There is an association between CP and cystic ﬁbrosis
(CF), therefore a sweat test should be performed to screen for CF as
a possible etiological factor in children. (GRADE 1/A, strong
agreement)
CP-III. Treatment of acute on CP in children
CP-III.1. The treatment for acute episodes of pancreatitis in pe-
diatric patients with CP does not differ from themanagement of the
initial episode. Nutrition for children during an episode of acute on
CP can be administered in the same way as in adult patients.
(GRADE 1/C, full agreement)
CP-III.2. The general use of antibiotics in children is not rec-
ommended in an acute exacerbation of CP. (Adult evidence level:
GRADE 1/C, strong agreement)
CP-IV. Imaging in CP in children
CP-IV.1. Transabdominal ultrasound, EUS, CT and MRI can be
used during themanagement of CP in childhood. (GRADE 1/B, strong
agreement)
CP-IV.2. Yes, EUS can be performed. This imaging examination is
a valid option in children for the assessment of biliary stones. In
addition, EUS is helpful during the treatment of the complications.
(GRADE 1/B, full agreement)
CP-IV.3. MRCP should be the ﬁrst choice for the cross-sectional
imaging of the pancreatic and biliary ducts. (GRADE 1/B, full
agreement)
CP-IV.4. The sensitivity of MRCP can be improved by the
administration of secretin. (GRADE 1/B, full agreement)
CP-V. Endoscopic, interventional and surgical treatment of CP in
children
CP-V.1. ERCP can be safely performed in children and should be
reserved for interventions in experienced centres. In the presence
of obstruction with concomitant signs or the presence of stones in
the pancreatic duct, therapeutic intervention (sphincterotomy,
stent insertion, dilatation of duct strictures, or stone extraction) by
ERCP can be chosen. Randomized studies on this subject are lacking
in the pediatric population. (GRADE 1/C, full agreement
CP-V.2. After failing conservative or endoscopic therapy, surgical
intervention may be indicated in children with CP, especially if
chronic pain persists and the child has frequent recurrent attacks
leading to numerous hospital stays. Preservation of pancreaticfunction should be the primary goal during surgical procedures.
(GRADE 1/C, full agreement)
CP-VI. Pain management in CP in children
CP-VI.1. The experience with pain management in pediatric CP
is limited. Endoscopic and/or surgical interventions may be needed
to control pain in pediatric CP. In general, non-narcotic analgesics
should be the ﬁrst line of therapy for pain and narcotics reserved for
uncontrollable pain. (GRADE 1/C, full agreement)
CP-VII. Enzyme replacement therapy (PERT) in CP in children
CP-VII.1. For PERT in pediatric CP, guidelines for cystic ﬁbrosis
induced exocrine pancreatic insufﬁciency (EPI) should be used.
Children less than 4 years of age should receive 1000 lipase units/kg
per meal; 1000e2500 lipase units/kg per meal for those >4 years of
age; and 40,000e50,000 units lipase/meal for children of adult size.
For snacks, half of the above dosing is recommended. (GRADE 1/C,
full agreement)
CP-VII.2. PERT in children and adolescents with CP should be
considered when growth and/or weight gain are unsatisfactory or
ongoing symptoms of EPI are present. (GRADE 1/C, strong
agreement)
CP-VII.3. Administration of acid suppressive drugs (either a
proton pump inhibitors (PPI) or H2 blockers) is recommended
when severe malabsorption occurs in spite of appropriate PERT in
children with CP. (GRADE 1/C, strong agreement)
Evidence review that served as the basis for the
recommendations
Acute pancreatitis
AP-I. Diagnosis and deﬁnition of acute pediatric pancreatitis
AP-I.1. What are the requirements for the diagnosis of AP?. A diag-
nosis of AP is achieved by meeting at least 2 of the following 3
criteria:1) abdominal pain; 2) serum lipase or serum amylase level
at least three times greater than the upper limit of normal; 3)
characteristic ﬁndings of AP with imaging methods [3]. (GRADE 1/B,
full agreement)
There were many attempts to put together the best diagnostic
criteria for AP in children. The best result was achieved when the
clinical symptoms, laboratory and imaging characteristics of AP
were considered together. Although lipase seems to be better
biomarker than amylase and CT has better diagnostic yield than US,
all of the modalities can be used during the diagnostic workup [8].
AP-I.2. What are the characteristics of abdominal pain which suggest
AP in children?. Diffuse, epigastric, persistent or minimally easing
abdominal pain suggests AP in childhood. (GRADE 1/C, full
agreement)
Abdominal pain is the leading symptom in 68e95% of the cases
[9,10] and in 62e89% of the cases it is localized to the epigastrium
[11e13]. Pain radiating to the back is present in only 1.6e5.6% of the
cases in children [13e15]. 12e20% of the pediatric patients with AP
have diffuse abdominal pain [1,16]. Abdominal pain is present in
only 29% of patients younger than 3 years old [10,17].
AP-I.3. What other clinical symptoms could suggest AP?. In children,
especially in infants and in toddlers, vomiting, irritability and
abdominal distension may suggest AP. (GRADE 1/B, full agreement)
The second most common symptom is vomiting, which occurs
in 45e85% of the patients. Less common symptoms are irritability,
abdominal discomfort, abdominal distension, tachycardia,
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children younger than 3 years old [10,17].
AP-I.4. What laboratory tests should be obtained to screen for
pancreatitis in a child with abdominal pain?. Measurement of serum
amylase and/or lipase among the routine laboratory tests is rec-
ommended in the presence of abdominal pain. (GRADE 1/C, full
agreement)
Studies show that the number of diagnosed with AP strongly
correlates with the frequency of tested serum amylase and lipase
levels [1]. According to international studies, serum amylase was
elevated in 50e85% of the cases and serum lipase was elevated in
77e100% of the cases. Elevated lipase levels were found in 100% of
the infants and toddlers with AP, however only 40e60% of them
had elevated amylase levels, based on two research centers' in-
vestigations. An Australian study clearly showed that elevation in
serum lipase contributed to the diagnosis more often than amylase
[8]. This is most likely a result of differences in digestive enzyme
expression during the ﬁrst several months of life [12,17]. This age
group needs a special approach for establishing the diagnosis. In a
signiﬁcant portion of children one or both enzyme levels were
elevated. Both parameters should be tested for optimal results [17].
AP-II. Etiology of acute pediatric pancreatitis in children
AP-II.1. What etiological factors should be considered in case of pe-
diatric AP?. Etiological factors that should be considered after the
diagnosis is reached are the following: biliary and pancreatic ab-
normalities, medication-associated, presence of underlying sys-
temic disease, trauma, genetic predisposition, infection, metabolic
disorders and autoimmune pancreatitis. (GRADE 1/C, full agreement)
AP-II.1.1. Biliary abnormalities: Pancreaticobiliary anomalies
should be ruled out in cases of ARP. (GRADE 2/C, full agreement)
This etiology includes pancreatitis due to gallstone impaction in
the distal common bile duct, microlithiasis with very small stones
or sludge, and pancreaticobiliary anomalies [18,19]. Biliary abnor-
malities as an etiology for pediatric pancreatitis are more common
than previously thought and, as in adults, most pediatric case series
report this as the most common reason for AP in children [10].
However, the frequency ranges widely in the literature, from 3 to
30%. Although each age group is affected, older children and
teenagers are at greatest risk [12]. In 10% of cases, gallstones are the
underlying cause in newborns and infants. Gallstones or other
biliary disorders should be investigated particularly if the patient
has jaundice and/or elevated transaminase levels and/or hyper-
bilirubinemia [12,17,20e22]. Pancreatobiliary anatomical anoma-
lies increase the risk of pancreatitis. These include pancreas
divisum, pancreaticobiliary maljunction (also known as a long
common channel), annular pancreas, and choledochal cysts.
Pancreas divisum occurs in about 7% of the general population [23].
Most patients with pancreas divisum never develop pancreatitis,
although there appears to be a higher number of pancreas divisum
cases among patients with pancreatitis compared to non-
pancreatitis control groups [12,20,24].
AP-II.1.2. Medications: The most common medications associ-
ated with AP in children are valproic acid, mesalazine, thiopurines,
and asparaginase [12,25].
AP-II.1.3. 13e34% of the cases are idiopathic [12,17,20,26],
although discovery of new genes genetic risk factors has been
narrowing the incidence of idiopathic pancreatitis [27].
AP-II.1.4. Systemic diseases: Based on observational epidemical
studies, AP in the setting of systemic diseases ranges from 3.5 to
48% [17,28]. It has been associated with sepsis, shock (with or
without sepsis), hemolytic uremic syndrome, systemic lupus ery-
thematosus and inﬂammatory bowel disease (IBD). Among these
diseases, hemolytic uremic syndrome had the highest prevalencerate. 2.7% of IBD patients will develop pancreatitis [10,20].
Conversely, 30% of patients with type 2 autoimmune pancreatitis
(also known as idiopathic duct centric pancreatitis, IDCP) have or
will develop IBD [29,30]. Celiac disease should also be ruled out in
accordance with the current diagnostic criteria. In a Swedish study,
patients with celiac disease had three times risk of developing
pancreatitis [31]. If a patient with celiac disease has abdominal pain
despite negative serology and a strictly followed diet, pancreatitis
should be considered. In another study, 7% of the adult patients
with AP and suspected stenosis of the papilla of Vater had celiac
disease [32].
AP-II.1.5. Traumatic injuries: Although the incidence of
pancreatitis caused by trauma is not as high as previously thought,
it is still an important etiological factor for pediatric pancreatitis.
Themost common cause is accidental blunt trauma, but child abuse
is also a notable factor. According to studies, in 10e40% of the cases
of AP, trauma was an etiological factor (motorcycle accident, sport
injury, accidental fall and child abuse) [17,18,20].
AP-II.1.6. Infections have been reported in less than 10% of the
cases. In some cases infections also caused fever and upper airway
symptoms, and in most cases mumps virus was detected. Other
viruses associated with pancreatitis include hepatitis A, rotavirus,
hepatitis E, varicella zoster virus and adenovirus. EpsteineBarr vi-
rus, cytomegalovirus, herpes simplex and Coxsackie B viruses can
also cause pancreatitis [12,17,18,20,32]. Diseases of viral or other
infectious origin (bacterial, parasite) should also be ruled out based
on the clinical picture (fever, diarrhea, airway or dermatological
symptoms) and other laboratory tests.
AP-II.1.7. Metabolic disorders are present in 2e7% of the cases.
The most common metabolic disorders are diabetic ketoacidosis,
hypertriglyceridemia and hypercalcemia [6,12,17,20,32,33]. It is
recommended to test serum triglycerides and serum calcium levels
in every child with AP.
AP-II.1.8. Genetic susceptibility: Pediatric AP and RAP often
develop in the background of genetic susceptibility and genetic
testing is warranted two or more episodes or even after an isolated
episode if there is a family history of AP or CP. Testing for patho-
genic variants in the PRSS1 [34], SPINK1 [35], CTRC [36], CPA1 [37]
and CFTR [38,39] genes and for the pathogenic CEL [40] hybrid
allele are recommended. Variants in the PRSS1 and CPA1 genesmay
be associated with a family history of pancreatitis or even auto-
somal dominant hereditary pancreatitis. Children with a single
episode of AP are at risk for developing a second episode. However,
genetic testing is [41] cumbersome and expensive. There is usually
no therapeutic consequence, but it may assist in long term
prognosis.
AP-II.1.9. Autoimmune pancreatitis:. Autoimmune CP type 1
(classic form of AIP) related to elevated IgG4 plasma levels is not
common diagnosed in children whereas Type 2 (often called idio-
pathic duct-centric CP) identical with the type seen in adults is
more likely to be found. Both diseases respond well to corticoste-
roid therapy and have low likelihood of recurrence [4].
AP-II.2. How should CF be ruled out in cases of AP in children?.
Cystic ﬁbrosis should be evaluated functionally by performing a
sweat chloride measurement (pilocarpine iontophoresis). (GRADE
2/C, full agreement)
AP-II.3. What kind of genetic testing is recommended in cases of pe-
diatric AP and CP?. In patients with a second episode of idiopathic
AP or ﬁrst episode of idiopathic AP and a family history of AP or CP,
full sequence analysis of PRSS1 [34], CPA1 [37], SPINK1 [35], CTRC
[36] and CFTR [38] gene exons and exon-intron boundaries and
testing for the CEL [40] gene pathogenic hybrid allele is recom-
mended in order to explore the etiological background. (GRADE 1/A,
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The presence of mutations in the above mentioned genes in-
creases the risk of ARP and CP. Hereditary pancreatitis associated
with mutations in PRSS1, especially p.R122H, that could consider-
ably increase the risk of pancreatic adenocarcinoma [34]. Knowing
the genetic risk factors may not alter the therapy, but it helps to
understand the disease's etiological background for the disease and
may lead to future targeted investigation.
AP-III. Prognostic factors in pediatric AP
AP-III.1. Which is the best clinical system to predict the severity of the
pediatric AP?. Currently, there is no pediatric-speciﬁc clinical
prognostic system which can be recommended. (GRADE 2/C, full
agreement)
In adult reports, systemic inﬂammatory response syndrome
(SIRS) is used for predicting the severity of AP, as persistent SIRS
may lead to organ failure. The revised Atlanta Criteria deﬁne severe
AP as AP with persistent organ failure for more than 48 h [42].
There are many adult pancreatitis severity scoring systems. These
include the Ranson [43], Glasgow [44], Modiﬁed Glasgow [45],
Bedside Index of Severity in AP (BISAP) [46], APACHE II [47,48], as
well as single serum biomarkers (i.e. the blood urea nitrogen, BUN)
[49] to assess the severity of the disease. The Balthazar score sys-
tem, which is based on CT ﬁndings, has 81% sensitivity, 76% spec-
iﬁcity, 62% positive predictive value, and a 90% negative predictive
value [50].
Several studies in children have also attempted to determine the
best scoring system to predict the development of severe AP.
DeBanto et al. reported the ﬁrst scoring. It was termed as the Pe-
diatric AP Score (PAPS) [28], and it was based on demographic,
clinical and laboratory values. It utilizes 4 parameters at admission
(age:<7, weight: <23 kg, white blood cell count: >18.5 G/l, LDH:
>2000 U/l) and 4more during the initial 48 h after admission (Ca2þ:
<8.3mg/dl, albumin: <2.6 g/dl, ﬂuid sequestration: >75 ml/kg/
48 h, and 48-h rise in BUN: >5mg/dl) to evaluate the severity of AP.
PAPS had a 70% sensitivity, 79% speciﬁcity, 91% negative predictive,
and 45% positive predictive values. In two large case series, how-
ever, the sensitivity for predicting severe AP using the PAPS, how-
ever, was low. Nonetheless, a high white blood cell count (>18.5 G/
l), low serum calcium level (<8.3mg/dl), high BUN level (>5mg/dl)
assessed at admission were good, independent predictive factors
[28,51].
In a retrospective study of children from Australia, serum lipase
values greater than or equal to 7 times the upper limit of normal in
the initial 24 h (or Day 1) after presentation to the hospital pre-
dicted the development of severe AP. The sensitivity (85%) and
negative predictive values (89%) were high, but the speciﬁcity (56%)
and positive predictive value (46%) were low [20]. The scoring
system had lower sensitivity and speciﬁcity in more recent vali-
dation reports [52,53]. The same original groupwent on to combine
this parameter along with measurements on Day 2 after presen-
tation of a greater than 50% reduction in the lipase fromDay 1 and a
trough calcium less than 2.15mmol/L [52]. This combination
improved the speciﬁcity to 89%, although the sensitivity was only
46%.
Szabo et al. examined pediatric severe AP cases from three
hospitals in the United States and identiﬁed changes in lipase, al-
bumin, and white blood cell count obtained within 24 h of admis-
sion to the hospital as predictors of severity [54]. Overall, the
studies suggest that unlike in a seminal [55], in children serum
lipase may provide some value in predicting pancreatitis severity
[56,57].
Suzuki et al. evaluated what they termed as the modiﬁed Min-
istry of Health, Labor andWelfare of Japan (JPN) scoring system in a
group of children with severe AP from Tokyo [58]. The original JPNscoring system consisted of several serum values and the partial
pressure of arterial oxygen, while the modiﬁed scoring had pedi-
atric SIRS, age, and weight added to it. Authors reported that the
JPN score had a sensitivity of 80% and speciﬁcity of 96%.
There are several reasons why predicting severe AP in children
has been difﬁcult. Published prognostic scoring systems in children
lack a standardized deﬁnition of the condition. Some include the
presence of pancreatic collections such as pseudocysts in the
deﬁnition, while others use the need for intensive care unit (ICU)
admission to deﬁne severe AP. It is almost needless to say that these
selections are subjectively determined at most institution. Another
issue is that few children comply with the strict deﬁnition of severe
AP imposed by the revised Atlanta Criteria of persistent organ
failure [10]. Some of the scoring systems, are also complicated and
impractical similarly to the adult ones. Future efforts should thus be
aimed at standardizing deﬁnitions, pooling patient cases in a multi-
center collaborations and balancing the ease of use with test
performance.
AP-IV. Imaging in pediatric AP
AP-IV.1. What is the ﬁrst-line imaging in suspected pediatric pancre-
atitis?. Transabdominal ultrasonography is recommended as a
ﬁrst-choice imaging technique in pediatric AP. (GRADE 1/B, full
agreement)
In children, no controlled trials have been conducted on the use
of imaging tools in suspected AP. Recommendations concerning
imaging methods are based on adult clinical experiences. Trans-
abdominal ultrasound is easy to perform, widely available, non-
invasive with no radiation exposure and no requirement for anes-
thesia in children, thus it is an optimal choice as a ﬁrst-line imaging
technique in AP. The diagnostic features of AP including, the
parenchymal changes, edema and peripancreatic ﬂuid collections
can all be readily recognized on transabdominal ultrasound.
Furthermore, it is a better imaging modality to assess for identify
choledocholithiasis or presence of stones in the common bile duct.
Transabdominal ultrasound has been performed in the majority of
children (56e84%) in suspected cases of AP [20,59]. According to
publications sonographic changes indicative of AP are found in
about one third to one half of pediatric patients [32,59].
AP-IV.2. What are the indications for early abdominal CT?.
Contrast-enhanced abdominal CT is recommended in clinical
deterioration in children as per adult guidelines. (Adult evidence
level: GRADE 1/C, full agreement)
In younger children, however, due to the radiation and the ne-
cessity of anesthesia/sedation, abdominal CT is not recommended
as a ﬁrst line investigation. In adults, contrast CT scan is the most
adequate modality for assessing parenchymal changes and the
complications of AP. The indications for contrast abdominal CT in
older children e similarly to adults e are the following: 1) diag-
nostic uncertainty, 2) unsuccessful conservative therapy, deterio-
rating clinical status, 3) estimation of the extent and necrosis in
severe AP, and 4) for assessment of complications [60e62].
Abdominal CT is the second most commonly used imaging
modality, yet inmost pediatric cases CT imaging is not necessary for
the diagnosis. In studies, abdominal CT was performed in a third of
suspected pediatric AP cases, however the sensitivity of the test
was low for parenchymal changes or for peripancreatic ﬂuid col-
lections (60e75%) [12,32].
AP-IV.3. Which imaging modalities are recommended in suspected
pancreatic necrosis and when?. If the clinical presentation of the
child suggests necrosis, contrast-enhanced abdominal CT or MRI is
recommended, as per adult guidelines. The optimal timing of the
scan is at least 72e96 h after presentation with pancreatitis. (Adult
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Regarding abdominal CT scan in practice, general pediatric
radiology guidelines are to be applied. CT scan can provide help in
complicated, severe cases, as these show necrosis and bleeding
more clearly than MRI [61].
AP-IV.4. When to perform ERCP in AP in children?. ERCP is not rec-
ommended for diagnostic purposes. (GRADE 1/C, strong agreement)
MRCP and EUS have lessened the importance of ERCP in the
diagnosis of pancreatobiliary diseases. ERCP could play a role along
with MRCP in the assessment and treatment of pancreatic duct
injuries in cases of pancreatic trauma [63,64] and can be performed
on children with appropriately sized tools, even with great care on
young infants. The effectiveness of the examination in children
exceeds 90%, while the complication rate is 4e9.5% [65,66]. In
children, the method requires anesthesia/sedation.
AP-IV.5. What are the main indications for endoscopic ultrasound
(EUS) in pediatric AP?. EUS is an useful method of examination in
children in cases of suspected autoimmune, biliary pancreatitis or
for treatment of local complications, such as pseudocysts or WON
(GRADE 2/C, full agreement)
Considering the size of the endoscope and the technical condi-
tions, the examination can be performed from about 5 years of age
with special indications, including the assessment of biliary stones
and the treatment of complications [59,64,67].
AP-IV.6. When should MRCP be performed in pediatric AP?.
MRCP is recommended for suspected pancreatic ductal leak or
injury or suspected biliary tract abnormalities. (GRADE 2/C, full
agreement)
The examination requires anesthesia or sedation if performed
on younger children, especially below the age of 6. MRCP is an
appropriate method of diagnostic modality of the biliary system in
children and should be the ﬁrst choice of imaging for pan-
creaticobiliary system in children [64,68].
AP-V. Treatment of pediatric AP
AP-V.1. Fluid therapy. No controlled pediatric trials are available on
the type and volume of parenteral ﬂuids used in ﬂuid resuscitation,
therefore we consider adult data [28].
AP-V.1.1. Which intravenous ﬂuids should be used in AP?.
Administration of dextrose containing crystalloids is recommended
as the initial choice for replacement ﬂuid therapy in AP. (GRADE 2/B,
full agreement)
Few studies have been conducted on the effects of parenteral
ﬂuids on the outcome of AP [69e71]. A multicenter study of 40
cases of adult AP showed a signiﬁcant decrease in SIRS incidence
with Ringer's solution compared to physiological saline [69]. In
adults the administration of plasma expanders is not recom-
mended based on current evidence [60,69]. Aggressive intravenous
hydration with lactated Ringer's solution appears to reduce the
development of post-ERCP pancreatitis and is not associated with
volume overload [72]. Other studies show no added beneﬁt from
lactated Ringer's solution compared to normal saline in terms of
mortality and the duration of hospital stay [73].
AP-V.1.2. What should be the volume and speed of ﬂuid replace-
ment?. Due to lack of unequivocal guidelines, early aggressive ﬂuid
management (a rate or more than 1.5e2 times the maintenance
rate of IV ﬂuids) is recommended in children in the ﬁrst 24 h.
(GRADE 2/C, full agreement)
Early ﬂuid replacement helps with the correction of hypo-
volemia, increases the perfusion of the pancreas, improves the
microcirculation and reduces necrosis. Neither adults nor children
have an established guideline related to the rate or volume of ﬂuidinfusion. Data shows that ﬂuid resuscitation within the window of
intervention (ﬁrst 24e72 h) reduces morbidity and mortality in
adults [60e62]. Additional ﬂuid correction should be tailored to the
child's hemodynamic status. The effects of ﬂuid resuscitation can be
measured by monitoring one or more of the following parameters:
1) Non-invasive methods such as pulse rate, blood pressure,
capillary reﬁll time, diuresis (0.5e1.0ml/kg/h); 2) invasive
methods, which should be employed in the intensive care unit
(ICU).
In children, aggressive ﬂuid hydration has been deﬁned as a rate
of more than 1.5e2 times themaintenance rate of IV ﬂuids, and that
was associated with improved outcomes with fewer ICU admis-
sions due to SIRS, and shortened hospital stays [74]. From multiple
adult studies it can be concluded that aggressive resuscitation is
associated with improved outcomes in AP, but overresuscitation
should be avoided. A regimen of IV ﬂuids within 4 h of diagnosis to
aggressive (20ml/kg bolus followed by 3ml/kg/h) vs. standard
(10ml/kg bolus followed by 1.5mg/kg/h) hydration with lactated
Ringer's solution was associated with greater rate of clinical
improvement [75].
AP-V.2. Pain management. Analgesia should be provided when
indicated. No speciﬁc pain management guidelines are available in
pediatric AP. The World Health Organization recommendations for
pain management in children should be considered [72]. In the
presence of mild pain, paracetamol and ibuprofen are the medi-
cines of choice. If pain severity associated with a medical illness is
assessed as moderate or severe, the administration of a strong
opioid is necessary. Medication should be administered on a reg-
ular schedule for persisting pain. Analgesics should be adminis-
tered to children by the simplest, most effective, and least painful
route, making oral formulations the most convenient and the least
expensive route of administration. The choice of alternative routes
of administration (intravenous, subcutaneous, rectal or trans-
dermal) when the oral route is not available should be based on
clinical judgement, availability and patient preference. The intra-
muscular route of administration is painful and is to be avoided
[76].
Thus far, randomized controlled trials (RTCs) comparing
different analgesics have been of low quality and have not found in
clear favor for any particular analgesic to be used for pain relief in
AP.
Opioid drugs, such as meperidine increase the tone of the
sphincter of Oddi, but clinical studies have failed to conﬁrm
declining outcomes associated with their use. Meperidine is a more
common choice, as it has fewer side effects, while the half-life if
morphine is longer.
AP-V.3. Nutrition. The nutrition of children with AP is carried out
according to recommendations based on clinical experience in
adults and the limited studies in pediatrics. No RCTs have been
done in children to address the role of nutrition in AP [18, 22, 23, 29,
30].
AP-V.3.1. When should oral feeding start?. Oral feeding can be
started as soon as tolerated even in the presence of systemic
inﬂammation and before the amylase or lipase values have
decreased. (Adult evidence level: GRADE 2/B, full agreement)
In mild AP oral feeding can be initiated within 24e48 h after
admission [77]. It is not necessary to wait for all the laboratory
parameters to normalize or for all pain to cease. A RCT in adults
found that an immediate normal diet was safe and led to shorter
hospital stay [78]. In another adult study, they administration of
solid food was recommended immediately instead of starting with
a liquid diet [79]. A pediatric study that examined the role of
nutrition in AP, showed that feeds within 24 h of admission are
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the group of patients that didn't received feeds [80,81].
AP-V.3.2. Should we choose tube feeding?. If adequate oral
feeding is not tolerated or the required energy cannot be achieved
by oral feeding within 72 h, enteral tube feeding is recommended.
(Adult evidence level: GRADE 1/A, full agreement)
Enteral feeding should be started orally, through nasogastric
tube [28] or through nasojejunal tube 24e48 h after admission, in
addition adequate ﬂuid therapy and pain management. Generally,
oral feeding can be initiated at this time in the majority of cases of
mild AP. In AP, early enteral nutrition has been found to reduce the
incidence of complications and improve outcomes regardless of the
severity of the disease compared to parenteral nutrition [31]. In
severe AP, the initiation of enteral nutrition within 48 h improved
outcomes compared to the initiation after 7 days. In a randomized
trial of 50 adult patients enteral feeding led to fewer infections,
organ failure, and reduced mortality and hospital stay [42,60,61].
AP-V.3.3. Should we choose nasojejunal or nasogastric tube
feeding?. In AP, enteral nutrition can be achieved either via naso-
gastric or nasojejunal tube feedings. (Adult evidence level: GRADE 1/
A, full agreement)
Several RCTs conducted in adults conﬁrmed that nasogastric
feeding is equivalent to the nasojejunal route with regard to com-
plications and clinical course [82e87]. Two RCTs with smaller
sample size group showed that nasogastric feeding is applicable
and safe [86,87]. However, we have note that some adult patients
might not tolerate nasogastric nutrition due to decreased gastric
emptying or worsening pain [60,88]. There are no comparative
studies comparing, gastric with jejunal feeding in pediatric AP.
AP-V.3.4. Which formulas should we use?. Elemental and poly-
meric formulas are both appropriate in the management of AP.
(Adult evidence level: GRADE 2/B, full agreement)
According to a recently published meta-analysis in which 20
RCTs were reviewed, polymeric formulas proved to be equivalent to
more expensive semi-elemental formulas with regard to tolera-
bility, infectious complications and mortality [89].
AP-V.3.5. Is there an indication for parenteral nutrition in AP?.
Complete parenteral nutrition is used as a second-line treatment in
AP, when enteral nutrition is not tolerated for the patient and
additional nutrition is necessary. (Adult evidence level: GRADE 1/A,
full agreement); The only indication for complete parenteral nutri-
tion is when enteral feeding is impossible due to prolonged ileus,
pancreatic ﬁstula or abdominal compartment syndrome [60].
AP-V.4. Antibiotic therapy
AP-V.4.1. Should prophylactic antibiotics be used in AP?.
Regardless of the severity of the pancreatitis or existing necrosis,
routine use of prophylactic antibiotics is not recommended. (Adult
evidence level: GRADE 1/B, strong agreement)
There are no controlled trials addressing antibiotic use in pe-
diatric AP, so following the adult guidelines is recommended [60].
AP-V.4.2. When should antibiotic therapy be used in pediatric AP?.
In cases of systemic infectious complications, cholangitis or sus-
pected infected pancreatic necrosis, antibiotic treatment is rec-
ommended. (GRADE 1/B, full agreement)
Most pediatricians recommend antibiotics if systemic symp-
toms (recurring fever, increasing abdominal pain and leukocytosis)
are present or in cases of biliary pancreatitis with cholangitis [20].
AP-VI. Management of biliary AP in children
Application of the guidelines for the treatment of biliary AP in
adults is recommended due to minimal data from pediatric studies.
Since the last pediatric AP guidelines were drafted on the role of
ERCP in biliary pancreatitis, adult studies have mainly focused onthe efﬁcacy and safety of ERCP with biliary pancreatitis.
AP-VI.1. What are the indications for ERCP and sphincterotomy in
biliary pancreatitis?
ERCP is not indicated in predicted mild biliary pancreatitis
without cholangitis. (Adult evidence level: GRADE 1/A, full
agreement)
ERCP is probably not indicated in predicted severe biliary
pancreatitis without cholangitis. (Adult evidence level: GRADE 1/B,
full agreement)
ERCP is probably indicated in biliary pancreatitis with common
bile duct obstruction. (Adult evidence level: GRADE 1/C, full
agreement)
ERCP is indicated in patients with biliary pancreatitis and
cholangitis. (Adult evidence level: GRADE 1/B, full agreement)
According to a meta-analysis of 7 RCTs with 757 adult patients
published in 2012, early ERCP did not reduce the frequency of
complications regardless of severity, although the analysis did
support the necessity for the procedure in cholangitis and biliary
obstruction [60,63,64,90].
AP-VI.2. What is the optimal timing of ERCP?
In cases of severe cholangitis ERCP should be done urgently
within 24 h. In other cases of cholangitis and/or obstruction. ERCP
should be performed within 72 h. (Adult evidence level: GRADE 1/B,
full agreement)
A recent retrospective adult study fromDenmark of 166 patients
with acute cholangitis who underwent ERCP found that the pres-
ence of AP did not inﬂuence outcome independent of cholangitis
[91]. Thus, studies on the timing of ERCP in adult patients with AP
could be helpful in patients with biliary AP and cholangitis. Only
one current retrospective study suggested that the timing of ERCP
did not affect outcome, but the majority of the adult patients in the
discovery (75%) and validation cohorts (80%) who had ERCP had the
procedure within 48 h of admission [92]. In the adult study from
Denmark, patients who underwent ERCP within 24 h had lower 30-
day mortality [91]. A prospective study of 199 consecutive adult
patients with cholangitis managed by ERCP showed that a delay of
more than 48 h was associated with a longer hospital stay and a
delay of more than 72 h was associated with other adverse out-
comes [93]. The most recent Tokyo guidelines recommend that the
timing of ERCP depends on the severity of cholangitis [94,95]. Pa-
tients with severe cholangitis deﬁned by the presence of organ
failure should undergo urgent biliary drainage. Patients with
moderate cholangitis, which is diagnosed when 2/5 criteria
(hyperbilirubinemia, high fever, leukocytosis, age 75 years or older,
and hypoalbuminemia) are met should have early biliary drainage
(within 24e48 h) and adult patients with mild cholangitis should
have biliary drainage when supportive measures such as antibiotic
therapy are not effective [96].
There are still no adult trials addressing the optimal timing of
ERCP in biliary pancreatitis, and since the timing of early ERCP is not
established (24e72 h), waiting 24e48 h is recommended as there
might be spontaneous improvement in biliary obstruction [60,61].
AP-VI.3. What is the optimal timing of cholecystectomy?
For uncomplicated biliary pancreatitis, cholecystectomy is rec-
ommended during the index admission, if possible or, if not
possible, within 30 days of the ﬁrst admission for mild
cholelythiasis-associated AP in children. Importantly, if the chole-
cystectomy is not performed the patient remains at risk of another
episode of AP and complications from gallstone obstruction. (Adult
evidence level: GRADE 1/B, full agreement; Pediatric evidence level:
GRADE 1/C, full agreement)
Two retrospective studies of early versus late cholecystectomy
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remain largely reliant on adult studies to help guide care.
A retrospective study from England of 670 cases of biliary
pancreatitis with gallstones demonstrated that cholecystectomy
before two weeks from the initial admission reduced the risk for
readmission by 58%without increasing the operative complications
[98]. A second pediatric study from the United States of 19 children
found that cholecystectomy done during the index admission did
not increase complications and shortened hospital stay after the
surgery [97]. Two RCTs of cholecystectomy during the index
admission versus delayed cholecystectomy in adults with biliary
pancreatitis have been reported [99,100]. A study from Taiwan
randomized 72 adult patients to early or delayed cholesystectomy
[100]. It was found that early laparoscopic cholecystectomy
signiﬁcantly decreased the risk of readmission (0% vs 44%,
p .0001) and was not associated with greater operative difﬁculty
or perioperative morbidity. A larger study from the Netherlands
randomized 266 adult patients to cholecystectomy during the in-
dex admission or delayed cholecystectomy [99]. Index admission
cholecystectomy reduced the rate of recurrent biliary disease (17%
vs 5%, p¼ .002) and had a low risk of surgical complications. In
addition, 5 retrospective studies of early versus late cholecystec-
tomy in biliary AP have been published [101e105]. Altogether over
19,000 patients were included in these studies. The deﬁnition of
early cholecystectomy ranged from surgery during the index
admission up to 30 days after the initial admission. All found lower
rates of readmission in the early surgery group. The risk for read-
mission in the early surgery groups ranged from 0 to 5% and in the
delayed surgery groups ranged from 13 to 45%. It remains unclear if
the risk for readmission increases during the 30 days after the ﬁrst
admission for biliary AP, which would support cholecystectomy
during the index admission. Two other factors are important to
consider in recommending index admission surgery. First, the
prospective study from England and one of the retrospective
studies showed shorter lengths of stay for adult patients who had
their surgery during the index admission [100,103]. A single
retrospective study showed no difference in hospital stay and the
others did not analyze that metric [105]. Second, delayed chole-
cystectomy requires another hospital visit and increases the overall
cost to the healthcare system [104].
Most of the current studies included patients with gallstone AP
whereas some also included patients with biliary sludge, elevated
serum transaminases or elevated bilirubin. The latter studies did
not stratify their analysis and the necessity of cholecystectomy is
yet to be decided in cases of ARP with biliary sludge.
In cases of severe biliary AP in adults and likely children, cho-
lecystectomy should be delayed by 6 weeks, by which time the
procedure is usually safe to perform according to clinical data
[60e62,97], although a longer delay may be necessary in particular
clinical circumstances.
AP-VII. Treatment of complications in pediatric AP
Due to the lack of evidence-based recommendations in children,
we take into account the guidelines used in adult treatment of
pancreatic necrosis and other complications of pancreatitis (infec-
ted pancreatic necrosis, pseudocysts, sterile or infected necrotic
ﬂuid collection).
There are no exact numbers for the pediatric incidence of
pancreatic necrosis, but this complication is rare. In a study con-
ducted by 7 centers, only one pediatric patient out of 380 devel-
oped necrosis [12,20,32]. Other studies found the incidence of
multiple organ failure and pancreatic necrosis to be under 10%
[32,106], while the incidence of pseudocysts ranged 10e38%
[32,106]. Themortality was 2e11%, mostly associated with systemicdiseases [107,108].AP-VII.1. What are the indications for intervention in pediatric
necrotizing pancreatitis?
Common indications for intervention in necrotizing pancreatitis
[60] include:
1. Conﬁrmed cases of infected necrotizing pancreatitis or if strong
suspicion of the same with decline in clinical status, especially
with WON
2. Unconﬁrmed cases of infected necrotizing pancreatitis with
multiple organ failure, especially with WON
3. Abdominal compartment syndrome
4. Ongoing acute bleeding
5. Bowel ischemia
6. WON causing gastric outlet syndrome, or bowel or biliary
obstruction
(Adult evidence level: GRADE 1/C, full agreement)
Pediatric data is limited to case reports and series [109e111].
Based on experiences in the treatment of adults, most cases of
sterile necrotizing pancreatitis can be treated without intervention.
WON usually develops over more than 4 weeks following presen-
tation with AP. A small percentage of the cases with conﬁrmed
infected necrosis, whose clinical status is stable, can be treatedwith
only antibiotics, without the need for drainage or necrosectomy
[112,113].AP-VII.2. What is the role of ﬁne-needle aspiration in the diagnosis of
infected pnecrotic peripancreatic ﬂuid accumulation?
Routine percutaneous FNA of peripancreatic necrotic collections
is unnecessary for conﬁrming bacterial infection, as clinical
(continuous fever, elevated inﬂammatory markers) and imaging
signs (gas in the collections) are valid predictors of infection in
majority of the cases. FNA could help with the conﬁrmation of
infection, but there is also a high prevalence of false negatives
(12e25%) [112]. (Adult evidence level GRADE 1/C, full agreement)
FNA is recommended in adults in cases without improvement in
clinical status weeks after the actual necrotizing pancreatitis,
where unequivocal clinical and imaging signs of infected pancreatic
necrosis are not present. No data are available as to whether FNA
would improve outcomes by reducing the time needed for the
diagnosis of infected necrosis and the initiation of antibiotic
treatment. No pediatric trials are available, only case studies [114].AP-VII.3. What is the optimal timing of intervention in suspected
and conﬁrmed cases of infected pancreatic necrosis?
Regarding the optimal timing of intervention in suspected and
conﬁrmed cases of infected pancreatic necrosis, only adult recom-
mendations are available, relevant clinical pediatric studies have
not been conducted. In conﬁrmed or suspected infected necrotizing
pancreatitis, invasive intervention (percutaneous catheter
drainage, endoscopic transluminal drainage or necrosectomy)
should be delayed as much as possible, but at least by 4 weeks after
the initial presentation so that the collection can transform into
WON. The timing of intervention should be balanced between the
need to intervene and the beneﬁts of delaying the intervention.
(Adult evidence level: GRADE 1/C, full agreement)
The timing of repeat interventions (repeat percutaneous
drainage, repeat endoscopic necrosectomy) should be based on
clinical and imaging criteria, there are no strong recommendations
on that matter in adults or children [60,112].
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suspected or conﬁrmed infected pancreatic necrosis?
The optimal intervention strategy in cases of suspected or
conﬁrmed infected necrotizing pancreatitis is initially imaging-
guided percutaneous (retroperitoneal) catheter drainage or endo-
scopic transluminal drainage, which, if necessary, can be followed
by endoscopic or surgical necrosectomy. (Adult evidence level:
GRADE 1/B, full agreement)
Pediatric data from case series suggest that endoscopic trans-
luminal drainage of WON or EUS-guided drainage using plastic or
fully covered self-expanding metal stents (FCSEMS) is safe and
efﬁcacious in children [67,109e111,115]. In adult cases of infected
necrotizing pancreatitis, percutaneous catheter drainage in itself
can prevent 23e50% of necrosectomies [60,112,113].
AP-VII.5. What are the indications for intervention in the presence of
a pseudocyst?
In the cases of an asymptomatic pancreatic pseudocysts,
regardless of size, location, and/or extension observation is
appropriate. When pancreatic pseudocysts are symptomatic,
endoscopic intervention should be the therapy of ﬁrst choice in
experienced centers. (Adult evidence level: GRADE 1/C, full
agreement)
RCTs on this matter have not been conducted in children. In
adults, spontaneous regression is rare if the pseudocyst is bigger
than 6 cm and persists over 4 weeks. Complicated or symptomatic
pseudocysts should be treated [112]. There are reports of successful
EUS-guided drainage of pseudocysts in children [106,109].
Acute recurrent pancreatitis (ARP) in children
ARP. Diagnosis and deﬁnition. It is deﬁned by at least 2 acute
attacks in the patient's lifetime without any evidence of CP. There
must be complete resolution of pain (1 month pain-free interval
between the diagnoses of AP, or complete normalization of serum
pancreatic enzyme levels (amylase and lipase), before the subse-
quent episode of AP is diagnosed, alongwith complete resolution of
pain symptoms, irrespective of a speciﬁc time interval between AP
episodes [3,5,116]. (GRADE 2/B, full agreement).
Chronic pancreatitis (CP) IN childhood
CP-I. Diagnosis and deﬁnition: CP is a progressive inﬂamma-
tory process that leads to the destruction of pancreatic parenchyma
and has a negative impact on pancreatic function. The diagnosis of
CP requires characteristic histological and morphological ﬁnding
with decreased pancreatic function (endocrine or exocrine) [3,5].
(GRADE 1/B, strong agreement)
CP-II. Etiology of childhood onset CP
CP-II.1. What kind of risk factors should be examined for CP in
childhood?. Genetic variations are the most common risk factors
for development of pediatric CP. (GRADE 1/A, full agreement) How-
ever, other risk factors such as obstruction, autoimmune and toxic
and metabolic factors also need to be examined. (GRADE 2/B, full
agreement)
A review by INSPPIRE suggests that themost common risk factor
for the development of CP is genetic alterations [27]. Other etio-
logical factors such as obstructive (ie: pancreas divisum, gallstones,
pancreaticobiliary malunion, biliary cyst, sphincter of Oddi
dysfunction, annular pancreas), autoimmune or toxic/metabolic (ie.
medications, smoking, alcohol) ones also can elevate the risk of
developing CP.
CP-II.2. Is there an association between CF and CP?. There is anassociation between CP and CF, therefore a sweat test should be
performed to screen for CF as a possible etiological factor in chil-
dren. (GRADE 1/A, strong agreement)
CF is an inﬂammatory disorder leading usually in utero to
pancreatic ﬁbrosis and insufﬁciency, but CF was excluded from the
older classiﬁcation systems because the special clinical features of
this disorder. 2% of all patients with CF and 10e15% of pancreatic
sufﬁcient patients with CF suffer from ARP [38,117]. Furthermore,
heterozygous carriers of CFTR mutations are overrepresented in
patients with idiopathic CP.
CP-III. Treatment of acute on CP in children
CP-III.1. How to treat acute episodes in patients with CP?.
The treatment for acute episodes in pediatric patients with CP does
not differ from the management of the initial episode. Nutrition for
children during an episode of acute on CP can be administered in
the same way as in adult patients. (GRADE 1/C, full agreement)
No controlled studies exist on nutritional management during
an acute episode of CP in the pediatric population. Early enteral
nutrition should be initiated, as in adults, in order to maintain the
intestinal barrier function.
CP-III.2. Should prophylactic antibiotics be administered during
the exacerbation of CP?. The general use of antibiotics in children is
not recommended in an acute exacerbation of CP. (Adult evidence
level: GRADE 1/C, strong agreement)
There are no controlled clinical studies addressing the use of
antibiotics during an acute episode of CP in childhood.
CP-IV. Imaging in CP in childhood. CP-IV.1 What kind of imaging
studies are recommended in CP in children? Transabdominal
ultrasound, EUS, CT and MRI can be used during the management
for CP in childhood. (GRADE 1/B, strong agreement)
Transabdominal ultrasound is the primary imaging technique to
examine CP in children because it is simple to perform and does not
involve radiation exposure. However, there are no comparative
studies on the validity of ultrasound imaging in children. The
beneﬁt of contrast-enhanced ultrasonography in children has not
been evaluated. In an older study involving 273 children and ado-
lescents between the ages of 0 and 19 years, normal standard
values for pancreatic size were determined by ultrasound. The
pancreatic head has a diameter of 1.0± 0.4 to 2.0± 0.5 cm in the
anterior-posterior plane (infant to young adulthood), the body of
the pancreas has a diameter of 0.6± 0.2 to 1.1± 0.3 cm, and the
pancreatic tail has a diameter of 1.0± 0.4 to 2.0± 0.4 cm. The main
growth of the pancreas takes place in the ﬁrst years and is subject
to high variation. Determining the size of the pancreas, therefore,
does not allow any conclusion to be drawn on the presence of CP
[59,64].
CP-IV.2. Can EUS be performed in childhood?. Yes, EUS can be
performed. This imaging examination is a valid option in children
for the assessment of biliary stones. In addition, EUS is helpful
during the treatment of the complications [99]. (GRADE 1/B, full
agreement)
Endoscopic ultrasound is technically possible in children as
early as 5 years of age and is primarily performed for diagnosing CP
by identifying calciﬁcations and aid in ﬁne-needle aspiration. It has
a higher sensitivity than MRCP in the diagnosis of CP [64,67,114].
CP-IV.3. When is MRCP performed in CP?. MRCP should be the
ﬁrst choice for the cross-sectional imaging of the pancreatic and
biliary ducts. (GRADE 1/B, full agreement)
MRCP is the imaging technique to demonstrate the pan-
creatobiliary tree in children because the examination is only
minimally invasive and does not involve radiation exposure. In
children <6 years, it is usually only possible to performMRCP under
general anesthesia [64,118].
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of MRCP can be improved by the administration of secretin. (GRADE
1/B, full agreement)
One study performed in children showed that the intravenous
application of secretin resulted in a better demonstration of
pancreatic side branches [118].
CP-V. Endoscopic and surgical treatment of CP in childhood
CP-V.1. When should ERCP be performed?. ERCP can be safely
performed in children and should be reserved for interventions in
experienced centres. In the presence of obstruction with concom-
itant signs or the presence of stones in the pancreatic duct, thera-
peutic intervention (sphincterotomy, stent insertion, dilation of
duct strictures, or stone extraction) by ERCP could be chosen.
Randomized studies in this subject are lacking in the pediatric
population. (GRADE 1/C, strong agreement)
RCTs on this subject are lacking in the pediatric population.
There are retrospective and prospective case series describing the
diagnostic use of ERCP and EUS and their application as interven-
tional therapy in pediatric patients with CP. ERCP-guided stent
insertion, stone removal and balloon dilation have been described,
as well as endoscopic ultrasound-guided drainage of symptomatic
pancreatic pseudocysts. When indicated, ERCP and EUS-based
interventional therapies should be tailored based on the child's
size and underlying disease, availability of equipment and well-
trained staff. The child's overall health (ASA classiﬁcation), size
and the facilities/endoscopists' preference may inﬂuence the use of
conscious sedation versus general anesthesia for these procedures
[114,119e121].
ERCP can safely be performed in children with a pooled
complication rate of about 6%, paralleling adults [65,66,122e127].
ERCP should not be used for diagnostic purposes in pediatric CP, but
reserved only for therapeutic interventions [128,129]. Therapeutic
ERCP can provide abdominal pain relief in selected childrenwith CP
[130]. Extracorporeal shock wave lithotripsy (ESWL) has been used
in conjunction with ERCP in a limited number of children with
hereditary pancreatitis [65,128]. It is not known whether ESWL
alone or in conjunction with ERCP would be an effective inter-
vention for pancreatic duct stones or calciﬁcations in pediatric CP.
ERCP is technically difﬁcult to perform in children <5 years of
age. EUS is only used for special indications in children and has a
higher sensitivity than MRCP in the diagnosis of CP [65,114,118].
CP-V.2. When is surgical treatment recommended in CP?.
After failing conservative or endoscopic therapy, surgical inter-
vention may be indicated in children with CP, especially if chronic
pain persists and the child has frequent recurrent attacks leading to
numerous hospital stays. Prevention of pancreatic function should
be the primary goal during surgical procedures. (GRADE 1/C strong
agreement)
It is difﬁcult to ﬁnd EBM guidelines regarding the indication for
surgery of the pancreas in pediatric patients with CP, timing of an
operation or the choice of surgical technique. Organ preservation
should be the goal, but total pancreatectomy with islet autotrans-
plant (TPIAT) should be considered as well [131,132]. EUS drainage
via endoscopic cystgastrostomy has become the standard of care
for drainage of large and symptomatic pancreatic pseudocysts in
children [115,133,134]. Percutaneous or surgical drainage can be
performed for a limited number of cases if endoscopic intervention
has failed, unsuccessful or not available [135]. Pancreatic duct
dissection, if present may require further endoscopic intervention
(i.e. stent placement) or surgical approaches [136,137].
CP-VI. Pain management in CP in children
CP-VI.1. What kind of pain therapy can be use in CP in childhood?.
The experience with pain management in pediatric CP is limited.Endoscopic and/or surgical interventions may be needed to control
pain. In general, non-narcotic analgesics should be the ﬁrst line of
therapy for pain, and narcotics reserved for uncontrollable pain.
(GRADE 1/C, strong agreement)
Abdominal pain is a common complaint in children with CP,
affecting ~80% children and leading to missed school days and
increased health care costs [27,129,138]. There is very little written
about pain management in childhood-onset CP. In the INSPPIRE
cohort, one-third of children with CP reported taking narcotics for
their pain [129]. In a survey to analyze the practice of pediatric
gastroenterologists who commonly treat children with CP, 75%
reported providing narcotics for CP-related pain, with 50% also
prescribing centrally acting agents, such as gabapentin [139].
Pain in CP can be managed medically and/or via endoscopic or
surgical approaches. The goal is to provide pain relief while pre-
serving pancreatic exocrine and endocrine function. Medical ther-
apies include acetaminophen, nonsteroidal anti-inﬂammatory
drugs and narcotic analgesics. Whenever possible, non-narcotic
analgesics should be the ﬁrst line of therapy, with narcotics used
only for uncontrollable pain. Endoscopic therapies should target
duct obstruction such as duct stone removal, stent placement,
stricture dilatation [140]. Surgical therapies involve drainage pro-
cedures that aim to decompress obstructed ducts, resection of
strictures and removal of pancreatic stones [130,140e142]. Total
pancreatectomy and islet autotransplantation may be indicated in
children with CP and intractable pain, unresponsive to other
measures [131,143].
CP-VII. Enzyme replacement for CP in childhood
CP-VII.1. When and what dosage of enzyme replacement therapy is
recommended?. For PERT [122] in pediatric CP, guidelines for CF-
induced EPI should be used. Children less than 4 years of age should
receive 1000 lipase units/kg per meal; 1000e2500 lipase units/kg
per meal should be used for those >4 years of age; 40,000 to 50,000
units lipase/meal for children of adult size. For snacks, half of the
dosing is recommended. (GRADE 1/C, full agreement)
If untreated, EPI can lead to fat malabsorption and nutritional
deﬁciencies in childrenwith CP. The frequency of EPI in pediatric CP
is not well established. In the INSPPIRE cohort, 34% of childrenwith
CP had EPI at the time of diagnosis [129]. In a Polish cohort,
malnutritionwas found in 25% of childrenwith CP [144]. If a child is
found to be exocrine pancreatic insufﬁcient by fecal elastase
(<100 mg/g) or 72 h fecal fat testing (coefﬁcient of fat absorption
>15% if< 6 months of age, > 7% for if> 6 months of age [145], PERT
is indicated. There are no guidelines on adequate dosing required
for childrenwith CP and EPI, but this is well-studied for CF. Children
with CF< 4 years of age typically require 1000 lipase units/kg per
meal; > 4years 1000 lipase units/kg per meal; while 25,000 to
40,000 units lipase/meal are used for adults [146]. For snacks, half
the dose is recommended. To prevent ﬁbrosing colonopathy, <
10,000 units of lipase/kg per day or <6000 units of lipase/kg per
meal should be used.
CP-VII.2. When do we have to think about PERT?. PERT in children
and adolescents with CP should be considered when growth and
weight gain are unsatisfactory or ongoing symptoms of EPI are
present. (GRADE 1/C, full agreement)
Frequent voluminous stools, fatty stools, increased ﬂatulence,
excessive appetite and reduced growth rate could indicate inade-
quate PERT. The substitution of a pancreatic lipase preparation by a
delayed-release formulation is effective and may be advantageous
given poor compliance with some preparations [147].
There are no published reports about optimizing PERT in chil-
drenwith CP. Therefore, we recommend following CF guidelines for
dose adjustments [146]. Brieﬂy, a child with CP can be considered to
have poor response to PERT, if he/she continues to have overt
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with steatorrhea and/or poor growth and weight gain. PERT dosing
can then be adjusted based on clinical response and/or 72 h fecal fat
testing.
CP-VII.3. What kind of therapy could be given in cases of malab-
sorption even with optimized PERT?. Administration of acid sup-
pression drugs (either a proton pump inhibitor (PPI) or H2 blockers)
is recommended when severe malabsorption occurs in spite of
appropriate PERT in children with CP. (GRADE 1/C, full agreement)
Increased gastrointestinal acidity has been reported in people
with CF due to several factors originating from a dysfunctional
CFTR, an ion channel involved in the transport of bicarbonate in
pancreatic/biliary ducts, duodenal Brunner glands and others
[148,149]. This can lead to inactivation of pancreatic enzymes in the
gut and impair fat digestion. Although it is not expected that
gastrointestinal pH will be as severely reduced in patients with CF,
gastric acid inhibition has been shown to increase the efﬁcacy of
PERT in adults [150]. There are no pediatric studies available.
Future perspectives
By writing these recommendations, not only has knowledge in
the management of pediatric AP and CP been summarized but also
areas that urgently require study have been identiﬁed. There is a
particular lack of knowledge concerning pain management both in
AP and CP, as well as prognostic scoring of the severity of AP.
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